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Abstract
The insertion of ablation needles towards pancreatic tumors demands excellent 
anatomical knowledge and interdisciplinary skills from the medical professional. 
While the placement of a single needle next to the structures at risk surrounding 
the pancreas is considered a challenging task, irreversible electroporation requires 
multiple needles to be placed in parallel at a specific location. Minimally invasive 
procedures complicate the already ambitious procedure, yet the ablation method 
bears potential to increase the overall survival for patients with locally advanced 
pancreatic cancer. Current studies require more clinical evidence regarding the effi-
cacy of irreversible electroporation in pancreatic cancer by means of randomized 
controlled, multicenter trials. However, the ablation treatment is currently applied 
in expert centers only, which is due to the complex task of the needle placement. 
Computer-assisted surgery has shown its potential in different fields of applica-
tions to improve the targeting of diseased tissue and the confidence of the medical 
professional. The application of computer-assisted needle navigation for pancreatic 
cancer ablation holds the prospect to make the procedure more reproducible and 
safer.
Keywords: pancreatic cancer, needle guidance, irreversible electroporation, 
Computer-assisted surgery
1. Introduction
Pancreatic cancer is one of the most aggressive types of cancer in the abdominal 
cavity with poor survival rates below 10% [1]. The reasons for the poor prognosis 
range from late detection of the cancer, vascular invasion, and difficult access due 
to the surrounding structures at risk. Attributable to the late detection, 80% of 
patients are not eligible for resection as they are diagnosed with locally advanced 
(30%), or metastatic pancreatic cancer (50%) [2]. Patients with locally advanced 
pancreatic cancer can benefit from alternatives such as radiotherapy, high-intensity 
focused ultrasound (HIFU), or ablation as a complementary treatment. Over the 
last decade, local ablative techniques have been used more frequently in patients 
without metastatic disease. Several techniques, all of which were primarily 
introduced in order to ablate liver metastases are in clinical use. Radiofrequency 
or microwave ablation, the two most widely established techniques, use thermal 
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energy. However, high temperatures not only destroy tumor tissue but also increase 
morbidity if applied too close to structures such as bile duct, portal vein, superior 
mesenteric vein, celiac artery, or superior mesenteric artery, which all run in close 
proximity to the pancreas [3–5]. On the other hand, irreversible electroporation 
(IRE) leads to cell death by using high-voltage electrical pulses without destroy-
ing vascular collagen [6]. IRE, in contrast to thermal ablative techniques, always 
requires at least two needles, and metallic implants and cardiac arrhythmias are 
contraindications for this technique [6]. Possible morbidity arises either from 
needle tract injuries (bleeding, local infection due to intestinal puncture) or 
from energy application-associated thrombosis or necrotic tissue leading again to 
infection.
Local ablative techniques are generally used in the context of a multimodal treat-
ment. Preoperative chemotherapy has been established in the most recent years for 
the multimodal treatment of borderline resectable and locally advanced pancreatic 
cancer to increase resectability [7]. Neoadjuvant chemoradiation has also been 
increasingly performed with favorable long-term outcomes [8]. However, response 
to these treatments cannot be evaluated adequately using radiologic criteria so far, 
thus directing decision-making regarding resection [9]. Similarly, IRE for pan-
creatic cancer has been facing the same problems, lacking reliable radiologic and 
clinical markers for the detection of response. Nevertheless, current studies have 
indicated that the antitumoral efficacy of IRE may be identified using immunologi-
cal parameters supporting the oncological benefits of IRE, additional to the electro-
porative effects of this ablative method on tumor cells [10, 11].
Neoadjuvant treatment for borderline resectable or locally advanced pancreatic 
cancer may allow resection in up to 78% of selected patients [12]. In this case, 
R0 resection status has been previously described as essential to reduce local and 
systemic recurrence and prolong survival [13]. However, due to local extension of 
tumor to involve vascular structures, R0 resection is more difficult to be achieved in 
patients with advanced disease and positive resection margins have been frequently 
been underestimated [14]. Therefore, in advanced disease, multimodal treatment 
concepts including induction therapy, followed by resection and concomitant IRE 
at the surgical margins have been proposed [15]. Several studies have shown the 
safety and feasibility of margin accentuation with intraoperative IRE during resec-
tion for borderline resectable and locally advanced pancreatic cancer. According 
to this concept, intraoperative IRE before complete transection could accentuate 
the negative-margin dissection of the retroperitoneal margin and its surrounding 
perivascular soft tissue as well as the perineural and mesenteric tissue adjacent to 
critical vascular structures [16, 17].
Additionally, current studies have even provided most promising results in 
terms of reduced local and distant progression, and superior overall survival 
when pancreatic resection and IRE are combined [16, 17]. Careful selection of 
patients eligible for this strategy, together with modern systemic therapy regi-
mens, may increase resectability and improve oncological outcomes in the near 
future [18].
In patients with borderline resectable and locally advanced pancreatic cancer, 
IRE was also identified as a valuable tool to offer consolidative disease control and 
symptom relief such as pain control and to support eradiation of the malignant 
lesion [19]. However, only few studies have evaluated the quality of life following 
IRE for pancreatic cancer [20]. In a recent study, 84 patients undergoing IRE 
for locally advanced pancreatic cancer were enrolled. Quality of life assessment 
indicated that IRE therapy does not impair the quality of life in the short term. 
Adverse post-interventional events such as increased insomnia and constipation 
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at 3 months and diarrhea at 6 months after IRE are most probably related to 
other clinical factors such as chemotherapy-associated toxicity. Therefore, IRE 
is not expected to adversely affect long-term quality of life in this patient cohort 
[21]. Further studies are required to examine quality of life following IRE in the 
long term.
The latest numbers on published pancreatic IRE cases investigated by Moris 
et al. [22] counted a total of 498 treatments and accentuate the lack of clinical 
evidence as an indicator for low numbers in pancreatic IRE treatments compared to 
other fields of application. While the procedures were either conducted percutane-
ously (n = 232) or open (n = 262), the laparoscopic approach (n = 4) played only a 
minor role [22].
IRE application requires the user to place the needles within a certain distance 
and angle to each other [23]. This makes the use of the ablation technique very 
difficult, especially when navigating the needles close to structures at risk. With 
respect to the laparoscopic needle placement, the long needles and decreased field 
of view add additional complexity to this task.
2. Navigate the pancreas
The workflow for pancreatic IRE treatments is divided into a preoperative plan-
ning and intraoperative navigation phase.
2.1 Preoperative needle planning
Tomographic images are acquired to identify the structures at risk in proximity 
to the tumor. These structures include vessels, bile ducts, and organs as visualized in 
Figure 1.
To assess suitable patients for the IRE treatment, patients are screened to 
determine possible access windows and the needle configuration depending on the 
treatment approach [24]. In addition, 3D reconstructions derived from the original 
images enhance the spatial understanding during the planning of the trajectories. 
Figure 1. 
Axial computed tomography image of a patient with LAPC where the tumor encapsulates the celiac artery.
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However, information regarding the preoperative IRE planning phase remains 
sparse in current literature.
2.2 Intraoperative needle placement
While the surgical (open or laparoscopic) approach provides advantages to 
mobilize the structures at risk to gain a better access window for the needles, the 
review of all eligible studies until August 2018 identified a morbidity of 36% for the 
surgical approach (89/247) compared to 24.3% for the percutaneous IRE approach 
(56/230) [22].
Atraumatic needle placement is key for a successful treatment outcome; thus, 
the needles need to be monitored with computed tomography (CT), magnetic 
resonance imaging (MRI), fluoroscopy, or with live ultrasound (US) depending on 
the treatment approach. As of today, there is no comparative study investigating 
CT vs. US-guided IRE needle placement. Both modalities may be used to check 
for proper needle placement [19, 25, 26]. However, since preoperative planning is 
typically conducted on CT images, it may be considered as the primary modality 
for guiding needle placement during the percutaneous intervention. The main 
disadvantage of increased radiation can be considerably reduced by complement-
ing computer-assisted navigation, as will be discussed later [27]. In addition, 
CT-guided procedures are less dependent on the experience of the user and offer 
the possibility to check immediately for post-interventional complications such as 
bleeding or thrombosis [27, 28].
The flexibility of the needles represents an additional challenge to keep the 
needles on track during the insertion. Dedicated hardware tools provide additional 
support to guide the needle to the specific location by reducing bending artifacts. 
The most basic form of needle guidance is the usage of the needle spacer provided 
by AngioDynamics (Latham, New York) to achieve the desired interelectrode 
distance, yet it does not prevent the needle from bending during the insertion [29]. 
Martin et al. [30, 31] emphasize the usage of a needle guide attached to the biplanar 
US probe for more precise needle placement and to keep the needle in the ultra-
sound plane. However, this approach limits the spatial freedom of the ultrasound 
transducer due to the static properties of the guide and aggravates the monitoring 
of structures at risk.
3. The doctor’s opinion
To elaborate on the necessity of dedicated planning and navigation assistance, 
we conducted a questionnaire with eight medical doctors (MDs). The study 
population consisted of MDs with specialty in HPB surgery (n = 7) and surgical 
oncology (1) active in USA (1), India (1) Turkey (1), Germany (1), Austria (1), 
and Switzerland (3). The MDs performed between 30 and 120 pancreatic surgeries 
annually (average value of 70 surgeries per year). The yearly number of IREs was 
situated between 0 and 20 treatments with an average number of 4.5. All ques-
tioned doctors performed the preoperative planning of IRE cases solely on tomo-
graphic images and occasionally in combination with reconstructed 3D models. Due 
to the complex anatomy with varying patient-specific structures at risk, all MDs 
argue in favor of a preoperative IRE planning tool, which makes use of imaging 
data in combination with reconstructed 3D models to verify the feasibility of needle 
configurations. Most of the pancreas specialists see a need for minimally invasive 
pancreas IRE (87.5%) as well as for intraoperative needle navigation (100%) (illus-
trated in Figure 2) [32].
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4. Computer-assisted needle guidance
Computer-assisted surgery (also known as stereotactic surgery) is established in 
fields like orthopedics and neurosurgery and emerged from “being just around the 
corner” to clinical routine of abdominal surgery over the recent decade [33]. When it 
comes to needle guidance, Beerman et al. [34] have reported the experiences from 1000 
consecutive cases using computer-assisted image-guidance in liver ablations. The key 
message of this study is the necessity of navigation solutions with respect to reproduc-
ibility in percutaneous, laparoscopic, and open interventions [34]. Another report 
investigating the accuracy between guided and manual probe placement shows a signifi-
cant advantage for the guided approach [35]. Martin et al. [36] discuss the advantages 
of computer assistance in the placement of single needles during a liver phantom study 
demonstrating that 95% of the participants were able to hit the center of the tumor using 
the computer-assisted approach compared to 65% with ultrasound (US) only.
The system used in the above studies was designed by CAScination (Bern, 
Switzerland) and provides guidance for interventional and surgical liver procedures 
(see Figure 3).
With regard to minimally invasive applications the system discriminates 
between the percutaneous and laparoscopic approach in the following aspects:
4.1 Percutaneous ablation
The navigation system supports the clinician during percutaneous ablation, which 
is performed in the intervention suite using computed tomography (CT) or cone-
beam CT (CBCT) imaging. The patient is under general anesthesia with respiratory 
motion control and positioned on a vacuum mattress. Retroreflective single mark-
ers are attached to the patient’s skin using a dedicated marker template. The single 
markers are detectable by the optical tracking camera and in the tomographic images 
and build the foundation for virtual to physical space registration. Furthermore, 
their spatial position is used for monitoring of patient movement throughout the 
procedure. The needle trajectories are then planned, navigated, and verified using CT 
images, with the possibility of planning IRE needle configurations (Figure 4).  
Figure 2. 
Result from questionnaire where the need for dedicated tools is highlighted to assist the clinician in the 
perioperative procedure.
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For the initial planning image, contrast-enhanced CT is the preferred choice to 
achieve a good discrimination between the structures of interest. To further enhance 
the planning procedure, a preoperative MRI image can be fused with the intraopera-
tive image data to visualize structures not traceable in the intraoperative CT.
Lachenmayer et al. [37] retrospectively analyzed the system in 174 percutaneous 
ablations of hepatocellular carcinoma (HCC) and reported a median lateral error 
of 3.2 (0.2–14.1) mm. They concluded that percutaneous, computer-assisted needle 
navigation is safe and efficient for treatment of HCC. Beyer et al. [38, 39] evaluated 
the system against manual, CT-fluoroscopically guided probe placement for IRE 
of liver tumors. The CAScination guidance (n = 10) was compared against manual 
guidance (n = 10) and they reported a significant decrease in planning time (55 vs. 
104 min, P < 0.001) and radiation exposure. The procedural accuracy, measured 
as the deviation of the IRE electrodes with respect to a defined reference electrode, 
was significantly higher for the navigated approach (2.2 vs. 3.3 mm mean deviation, 
P < 0.001) [39].
Figure 3. 
Setup for percutaneous needle insertion. Aiming device (A), touch monitors (B), optical tracking camera (C), 
patient markers (D).
Figure 4. 
Percutaneous workflow from left to right: Patient marker attachment, CT-based IRE trajectory planning, 
positioning of aiming device, and needle placement control.
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4.2 Laparoscopic ablation
The system for laparoscopic needle navigation relies on a surface landmark 
registration in which distinct points on the organ surface are sampled with tracked 
instruments and matched with the corresponding points from available patient 
image data. These data include preoperative CT images with optional 3D recon-
structions from structures of interest. Guidance is achieved by tracking of the 
ablation needle using retroreflective markers attached to the hand piece (Figure 5).
A major drawback for the surface landmark-based registration approach is organ 
deformation due to pneumoperitoneum, which downgrades navigation accuracy on 
preoperative image data. Intraoperative CT imaging would help to reduce deforma-
tion artifacts; however, this requires the availability of a hybrid OR [40]. Prevost et 
al. [41] investigated the laparoscopic guidance solution for liver resection and abla-
tion in 10 cases with the main conclusion being that the navigation system enhances 
the explorative phase, yet the registration accuracy was not sufficient for reliable 
tool navigation. Stillström et al. [42] pioneered in the application of computer 
assistance in laparoscopic pancreas IRE. They reported the feasibility of image-
guided navigation in the operating theater even though the system was mainly used 
for orientation purposes.
4.3 Needle guidance
The CAScination system distinguishes between two approaches for needle 
guidance, namely active and passive guidance. The active guidance (freehand 
approach) makes use of instrument calibration to determine the needle tip with 
respect to the marker shield attached to the hand piece of the needle, whereas 
passive guidance makes use of a tracked mechanical arm (aiming device approach) 
which is pre-calibrated due to known geometric properties. While the former 
provides the advantage of visualizing the needle tip during the insertion to obtain 
an active depth control, it is affected by errors resulting from the calibration and 
needle bending. The latter is not affected by the calibration error and reduces the 
bending artifacts by means of brackets guiding the needle along the oriented path. 
During needle insertion, the lateral deviation from the original plan is of high 
significance as it may require needle repositioning. Wallach et al. [43] compared 
the two approaches during a phantom study with 25 needle punctures on a nonrigid 
phantom. The resulting lateral error of the needle to the defined target was found to 
be significantly lower with the aiming device (2.3 ± 1.3 mm vs. 4.2 ± 2.0 mm) [43].
Figure 5. 
Laparoscopic workflow from left to right: preoperative image segmentation, optical instrument calibration, 
landmark-based registration, targeting with active depth control.
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4.4 Alternative navigation solutions
There are a number of navigation solutions for abdominal organs on the market. 
These devices share the same fundamental functional principles and provide a 
different range of functionalities, which can be used in the setting of IRE on the 
pancreas. Given the high accuracy requirements and the complexity in needles 
placement relative to a number of risk structures, we deem functionality for multi-
needle planning as well as accurate needle guidance as mandatory requirements for 
navigated IRE on the pancreas. The following paragraphs present different available 
navigation solutions and evaluate them with respect to these two requirements.
The IMACTIS® CT (Imactis SAS, La Tronche, France) solution is designed for 
percutaneous interventions using CT imaging and electromagnetic instrument 
tracking. The device was applied on different target organs and available literature 
includes an assessment of needle positioning accuracy and time requirements in 
a prospective randomized trial. The median Euclidean error [interquartile range] 
using the computer-assisted approach was found to be 4.1 mm [2.7–9.1 mm] 
compared to 8.9 mm [4.9–15.1 mm] for the non-navigated group for a total of 120 
patients [44]. This shows that IMACTIS® CT has the potential to reach sufficient 
accuracy for IRE needle placement. Its shortcoming with respect to the application 
of pancreatic IRE lies in the fact that the device has no functionality for needle plan-
ning and multi-needle treatments.
The MAXIO (Perfint Healthcare, Florence, Oregon, USA) is used in CT-guided, 
percutaneous interventions and includes a robotic arm for needle placement. The 
device comprises a planning software supporting single- as well as multi-needle 
planning for different needle types. Beyer et al. [38] investigated the MAXIO with 
respect to procedural accuracy in a retrospective study of 40 cases of liver IRE 
conducted by an experienced interventional radiologist. Out of these, 19 were con-
ducted using manual needle placement under CT fluoroscopy guidance and 21 with 
guidance of the robotic system. To calculate the procedural accuracy, an oblique 
slice was placed at the needle tip closest to the tumor with the normal pointing 
along the needle direction. Each needle tip was successively projected on the slice 
translated 3 cm from the tip toward the hand piece to calculate the distance to the 
needle center. The resulting accuracy was significantly improved when comparing 
the robotic approach to freehand needle placements (2.2 vs. 3.1 mm) [38].
The navigation system Explorer (Pathfinder) is designed for needle guidance 
in open liver surgery and is based on optical instrument tracking (same functional 
principle as CAS-One for the laparoscopic use case). A study by Bond et al. [45] 
investigated needle guidance accuracy and required time in a randomized con-
trolled trial of IRE for pancreatic cancer. The application of the Explorer device 
decreased time for needle placement from 20 to 11 min while reaching an accuracy 
of 3.4 mm in relative spacing between the needles. The accuracy of needle place-
ment with respect to the target anatomy is expected to be lower as the publication 
reports average fiducial registration errors of 10.8 mm. The authors conclude that 
the main benefit of the navigated approach is the increase of the surgeon’s confi-
dence to localize the needle using stereotactic navigation. The image to physical 
space registration is seen as the biggest obstacle to achieve a reliable overlay between 
the preoperative plan and the intraoperative scene.
Further guidance solutions for pancreatic IRE potentially include the use of 
ultrasound fusion devices such as those used in percutaneous ablation treatment on 
the liver. While providing needle guidance under real-time feedback, there are no 
devices providing multi-needle planning functionality together with ultrasound-
based needle navigation. To our knowledge, there are no reports on the usage of 
ultrasound-fusion and navigation devices in the setting of pancreatic IRE.
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5. Computer-assisted pancreas navigation
Existing computer-assisted navigation solutions address the needs of the pan-
creatic MDs to some extent, yet there remains room for improvement. The applica-
tion of IRE as a treatment for pancreatic cancer bears additional challenges, which 
are partially covered by existing solutions:
• The IRE needle configuration is dependent on the tumor size. The optimal 
spacing between two IRE probes shall be situated between 1.5 and 2.5 cm to 
achieve a successful treatment outcome [23].
• Multiple structures at risk surrounding the pancreas require the probes to be 
planned and placed according to safety criteria to reduce insertion related 
complications [22, 25].
• The flexible IRE needles increase the risk of deformation during the insertion 
process.
• A homogeneous ablation field along the active zone of the IRE needles is 
dependent on the parallelism of the inserted needles [46].
Low usage numbers of stereotactic needle guidance in the pancreatic use case 
highlights that not all problems have yet been addressed to support the complete 
perioperative procedure. A study recently published by He et al. [47] demon-
strated the feasibility of robot-assisted percutaneous IRE treatment of pancreatic 
head cancer in 9 cases. With respect to spatial accuracy, the stereotactic percu-
taneous navigation outperformed the stereotactic laparoscopic navigation in 
existing reporting. Therefore, stereotactic percutaneous needle guidance can be 
seen as the foundation to achieve reliable and reproducible navigation results. 
Yet, it only constructs one part of a dedicated computer-assisted pancreatic IRE 
workflow.
5.1 IRE planning tool
Preoperative image data are essential to generate a safe and feasible ablation plan 
with an optimal needle configuration to treat the tumor. We developed a dedicated 
preoperative planning tool, which makes use of CT/MRI image data in combination 
with 3D reconstructions to simulate IRE needle configurations. The tool allows the 
MD to define target and entry positions on multiplanar reconstructions (MPR) of 
the tomographic images with the possibility to select different needle configura-
tions (layout and spacing). Under consideration of IRE-related constraints (spacing 
and parallelism), the trajectories can be optimized to cover the region of interest. 
The segmentations are conducted by a radiologist using dedicated software and can 
be tailored upon the type of intervention. Unlike for the open approach, preopera-
tive segmentations for a percutaneous approach could include structures like the 
stomach, colon, or liver as well. This information is beneficial for the determination 
of the access window and to evaluate risk structures in the vicinity of the needles.
The planning tool was evaluated in the course of a clinical study of IRE in a 
laparotomy setting at the local hospital (Inselspital, Bern, Switzerland). Figure 6  
demonstrates the application of the planning tool to 1 out of 10 cases. During the 
surgery, the decision was to place the needles according to plan # 1 as the superior 
mesenteric vein was not mobilizable enough to obtain a window for the inferior 
right needle in #2. The 3D planning tool proved beneficial in both the preoperative 
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as well as intraoperative phase as it increased the MDs spatial understanding during 
the generation of the ablation plan.
5.2 Aiming for parallelism
To transfer the predefined ablation plan from theory to practice, a navigation 
system can take remedial action. Visual guidance information provided by the 
navigation system aids the clinician to position the ablation needle relative to the 
defined path. The computer-assisted navigation solutions proved to be advantageous 
for IRE needle guidance in terms of procedural accuracy compared to the manual, 
CT-fluoroscopically guided approach [38, 39]. Whereas these navigation systems 
make use of a mechanical guide, navigation systems such as the IMACTIS® CT 
require the user to actively align and insert the needle. This might cause a challenge 
for less experienced clinicians in needle guidance. We have therefore compared the 
two computer-assisted navigation approaches discussed in Section 4.3 by means of a 
phantom study with a similar setup as in [43]. Firstly, the needle was actively tracked 
(freehand approach), and secondly the mechanical arm (aiming device approach) 
was used. Seven participants were requested to place three needles (17 g, 15 cm) using 
each approach around a tumor encompassing the celiac artery in an artificial, flex-
ible phantom. Three trajectories were predefined on the navigation system and each 
user received an instructional training. The calibration procedure for the freehand 
approach was conducted upfront to minimize the calibration error. The starting 
sequence was randomized, the needle control scan was conducted with a mobile 
C-arm, and the validation again conducted with the CAScination system by means of 
image to image fusion.
The mean lateral error for the aiming-device approach (2.4 ± 0.7 mm) was found 
to be similar compared to the lateral error (2.3 ± 1.3 mm) obtained in [43]. The error 
for the freehand approach resulted in a larger mean error (6.7 ± 1.7 mm) compared 
to the results from [43] (4.2 ± 2.0 mm), which can be explained by the larger group 
of participants with varying experience in manual needle placement. Parallelism of 
the needles for both approaches was calculated according to the method used in [38] 
where an oblique slice was placed at the needle closest to the tumor with the normal 
pointing along the needle direction. Each needle tip was successively projected on the 
plane translated 3 cm from the tip toward the handpiece to calculate the distance to the 
needle center. With a total of 14 samples per approach, the resulting mean Euclidean 
error was significantly lower for the aiming device than for the freehand approach 
(1.5 ± 0.7 mm versus 2.4 ± 1.1 mm) with a p-value of 0.014 (see Figure 7). However, 
Figure 6. 
Preoperative plan on axial plane with segmentation overlay (left). Two IRE configurations with 3D 
reconstructions (middle). Image plane at needle tip in direction of the trajectory to visualize distances between 
the needles in millimeter (right).
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these results should not be compared with the findings by Beyer et al. [38, 39] due to 
the setup of the studies (phantom vs. in vivo), yet their reported decrease of the error 
using the computer-assisted navigation goes along with the findings by our group.
6. Future directions of IRE in pancreatic cancer
Given the severity and decreased overall survival of patients diagnosed with 
locally advanced pancreatic cancer, there is a driving need for treatment alternatives 
to conventional chemo/radiation therapy. The minimally invasive application of IRE 
shows potential regarding an increase of the progression-free survival time and quality 
of life [48]. However, these interventions require highly experienced medical profes-
sionals as needles need to be navigated close to multiple structures at risk. Computer 
assistance plays a major role in all types of procedures where spatial accuracy needs 
to be delivered in order to achieve a successful treatment outcome. As mentioned in 
Morris et al. [22] there is a need for multicenter, randomized, prospective trials to 
determine the efficacy of IRE treatment in the pancreatic use case. To conduct IRE 
treatments on the pancreas, computer assistance holds the potential to standardize the 
workflow and to enable highly accurate needle placement independent on outstanding 
multidisciplinary skills, which are typically found in high expert centers.
6.1 Patient screening
The evaluation of suitable patients for IRE is a crucial step to achieve a positive 
treatment outcome. The Miami Protocol lists patients’ criteria including among oth-
ers the performance status, lesion size, and access path [24]. An important criterion 
is stated by the access path, which requires an excellent radiological understanding 
Figure 7. 
Comparison of aiming device versus freehand for a specific participant. The top row visualizes the calculation 
of the Euclidean error between the aiming device (A) and freehand (B) approach. Volume rendering from 
control CT of aiming device (C) and freehand (D) guidance highlights the bending of the needle in the 
freehand approach.
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due to the difficulty of planning multiple trajectories solely on tomographic images. 
This coincides with the opinions of the MDs who consider conventional 2D plan-
ning to be insufficient. A dedicated planning tool would enhance the preoperative 
procedure as multiple access paths can be planned relative to the patient’s anatomy 
and structures at risk better identified. This requires precise anatomical segmenta-
tions from the radiological department, which is, especially for the pancreatic use 
case, a time-consuming task.
6.2 Artificial intelligence-driven segmentation
To plan multiple trajectories, especially in a percutaneous fashion, multiple 
organs surrounding the pancreas need to be considered. To obtain a good spatial 
understanding of the acquired tomographic images, 3D representations from the 
structures of interest help in the decision-making process. Where time may be 
sufficiently available in the preoperative phase, it is a valuable asset during the 
intraoperative phase. Therefore, a compromise between accuracy and processing 
time must be chosen to enable 3D reconstruction from intraoperative tomographic 
images. Deep learning-based segmentation has shown its potential in multiple 
fields including medical imaging tasks [49]. Segmentation of the pancreas is seen 
as a challenging task due to the dependency on good delineation of the organ to its 
adjacent structures in the abdominal cavity [50]. To segment the complete range of 
structure needed for pancreas IRE planning, Roth et al. [51] describe a multi-scale 
pyramid of 3D fully convolutional network. The reported network was trained 
and validated using 377 clinical CT datasets with annotated organs and vessels. 
The performance of the system was measured by means of the DICE score, which 
represents the similarity between the automatic segmentations from CT images not 
used for training and their manual annotations. The network was able to achieve a 
Dice score close to 90% on average, which holds promising aspects for automatic, 
intraoperative segmentation [51].
6.3 Automatic trajectory optimization
Based on the patient-specific data, automatic trajectories can be computed 
according to permitted access paths while securing a specific distance to structures 
at risk [52]. The optimization for the IRE use case would further depend on the 
needle configuration, interelectrode spacing, and parallelism constraints.
6.4 Ablation zone prediction
The application of IRE lacks the possibility of ablation validation as, in contrast 
to thermal ablation, the ablation zone cannot be monitored in real time. Therefore, 
the clinician must fully rely on the ablation zone prediction from the manufacturer, 
which is based on mathematical and ex vivo models. However, ultrasound elastog-
raphy has shown potential to distinct ablated tissue from normal liver parenchyma 
with respect to tissue stiffness, which peaked 4 hours post-ablation [53]. Based on 
the ultrasound characteristics at 2 hours post-ablation in combination with histo-
pathology findings, Bhutiani et al. [54] have shown the mismatch of current models 
with in vivo-generated ablation volumes in porcine liver and spleen.
6.5 From theory to practice
The placement of needles according to the defined trajectories is seen as a chal-
lenging task, especially for medical professionals who are not versatile in the art of 
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needle insertion. Therefore, navigation solutions are of great interest to empower 
these clinicians to conduct safe procedures with IRE in the pancreas. Needle naviga-
tion by means of software and hardware guidance is best applicable to improve the 
spatial accuracy and to spare structures at risk. Especially the aiming device has 
shown its value in the reduction of needle bending for inexperienced users. Further 
improvement toward parallel insertion of the electrodes is required since this is, 
next to the interelectrode spacing, an important aspect to achieve a homogeneous 
ablation volume.
7. Conclusion
Minimally invasive ablation treatment of locally advanced pancreatic cancer is 
a promising, yet challenging task. The application of the IRE as a treatment addi-
tion to conventional chemotherapy with optional radiotherapy has the potential to 
increase the overall survival, which needs further investigation upon its efficacy 
by means of randomized-controlled, multicenter studies. The percutaneous 
application of IRE demands a sophisticated workflow from preoperative screening 
of suitable patients to intraoperative implementation of the predefined ablation 
plan. Computer-assisted surgery systems can aid the clinician during these steps 
with dedicated software and hardware tools to achieve reproducible and effective 
treatments.
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